8-K: Applied DNA Sciences Announces 1-for-50 Reverse Stock Split to Regain Nasdaq Compliance

Applied DNA Sciences will implement a 1-for-50 reverse stock split, effective March 14, 2025, to meet Nasdaq's minimum bid price requirement.

Summary

• Applied DNA Sciences (APDN) announced a 1-for-50 reverse stock split of its common stock.
• The reverse stock split will be effective on March 14, 2025, at 12:01 a.m. Eastern Time.
• Trading on a split-adjusted basis will begin on the Nasdaq Capital Market on the same day.
• The company's ticker symbol will remain APDN.
• The new CUSIP number for the common stock is 03815U508.
• The reverse stock split will reduce the number of outstanding shares from approximately 55.2 million to approximately 1.1 million.
• The total authorized number of shares will not be reduced.
• Fractional shares will be rounded up to the nearest whole share.
• The reverse stock split is intended to bring the company into compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• Stockholders holding shares in book-entry form or through a bank/broker do not need to take any action.

Sentiment

Score: 5

Explanation: The announcement is a neutral corporate action. While it addresses a compliance issue, it doesn't inherently signal positive or negative business performance. The long-term impact depends on the company's ability to improve its financial results.

Positives

• The reverse stock split aims to bring the company into compliance with Nasdaq's listing requirements.
• Stockholders holding shares in book-entry form or through a bank/broker do not need to take any action.

Risks

• The company's history of net losses and limited financial resources could impact future performance.
• Unknown future demand for its biotherapeutics products and services poses a risk.
• The amount of revenues and profits from Linea IVT and Linea DNA platforms is uncertain.
• There has never been clinical trial material and/or a commercial drug product produced utilizing the LineaDNA and/or Linea IVT platforms.
• The amount of revenues and profits that will result from its TR8 PGx testing service is unknown.

Future Outlook

The company anticipates that the reverse stock split will enable it to regain compliance with Nasdaq listing standards and position it for long-term growth and value creation.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low share prices. This action is intended to increase the stock price and maintain listing compliance, which can improve investor confidence and access to capital.

Comparison to Industry Standards

• Many biotechnology companies facing similar challenges with Nasdaq compliance have implemented reverse stock splits.
• For example, companies like XOMA Corporation and BioSpecifics Technologies Corp. have previously used reverse stock splits to maintain their Nasdaq listings.
• The success of a reverse stock split in maintaining compliance and improving long-term value depends on the company's underlying business fundamentals and its ability to execute its strategic plan.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but the proportionate value should remain the same.
• The reverse stock split aims to maintain the company's listing on the Nasdaq, which could benefit shareholders by maintaining liquidity and access to capital markets.

Next Steps

• The company will begin trading on a split-adjusted basis on March 14, 2025.
• Equiniti Trust Company, the company's transfer agent, will provide information to stockholders regarding their stock ownership following the reverse stock split.

Key Dates